A bioinformatics firm spun out of Cold Spring Harbor Laboratory, Envisagenics is an Artificial Intelligence-driven biotech structured around discovery of novel RNA splicing variants that cause cancer and other genetic diseases. A woman-owned and minority-led firm - currently resident in JLABS@NYC - the firm's principal technology is the SpliceCore® discovery platform. This involves re-envisioning the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing.... more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing variants that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders. Having its own internally developed RNA therapeutic programs, the firm partners with biopharmaceutical companies and academic institutions to advance their drug discovery capabilities.